What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate and compare the clinical performance of the DH3 HPV detection method and the HC2 detection method in high - risk HPV infection in cervical cancer screening. Specifically, the study aims to answer the following questions: 1. **Consistency between the two detection methods**: How consistent are the DH3 HPV detection method and the HC2 detection method in detecting high - risk HPV infection? Are there significant differences? 2. **Sensitivity and specificity**: Are the sensitivity and specificity of these two methods equivalent in detecting cervical intraepithelial neoplasia (CIN) grade 2 or higher (CIN2 +) and CIN grade 3 or higher (CIN3 +) lesions? 3. **Performance in long - term follow - up**: During the 3 - year follow - up period, do the two detection methods maintain consistent performance? 4. **Application potential in the primary screening strategy**: Can the DH3 HPV detection method replace the HC2 detection method in the primary screening strategy, especially when HPV16/18 genotyping is carried out simultaneously? ### Research background Cervical cancer is the fourth most common cancer among women worldwide. Almost all cervical cancers and their precursor lesions are caused by persistent high - risk human papillomavirus (hrHPV) infection. Hybrid Capture 2 (HC2) is currently one of the most commonly used high - risk HPV detection methods and is considered the gold standard. However, HC2 cannot distinguish between HPV16 and 18 and other high - risk types of HPV, which limits its application in cervical cancer screening. The DH3 HPV detection method is a new method based on the hybrid capture technique. It can detect 14 high - risk types of HPV and simultaneously perform HPV16/18 genotyping. Therefore, researchers hope to evaluate the potential advantages of the DH3 HPV detection method in cervical cancer screening by comparing these two methods. ### Main findings - **Consistency**: The overall consistency between the DH3 HPV detection method and the HC2 detection method is 99.2%, and the Kappa coefficient is 0.938, indicating a very high degree of agreement between the two. - **Sensitivity and specificity**: At baseline, the sensitivity of the DH3 HPV detection method for CIN2 + and CIN3 + is 98.67% and 97.78% respectively, which is equivalent to that of the HC2 detection method. There are also no significant differences in terms of specificity. - **Long - term follow - up**: During the 3 - year follow - up period, the sensitivity and specificity of the two detection methods for CIN2 + and CIN3 + remain consistent. - **Application in the primary screening strategy**: In the primary screening strategy, using the DH3 HPV detection method and triaging through HPV16/18 genotyping and/or liquid - based cytology (LBC) can significantly increase the immediate sensitivity to 92%, while the immediate sensitivity of the HC2 detection method through LBC triaging is only 74.67%. ### Conclusion The research results show that the DH3 HPV detection method is equivalent to the HC2 detection method in detecting high - risk HPV infection and identifying high - grade cervical lesions, and has potential advantages in the primary screening strategy, especially when HPV16/18 genotyping can be carried out simultaneously. Therefore, the DH3 HPV detection method can be regarded as an effective alternative to the HC2 detection method.

Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data

Use of High-Risk Human Papiilomavirus DNA Testing to Deal with Atypical Squamous Cells-Can-not Exclude HSIL

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

A Parallel Study of Carehpv and Hybrid Capture 2 Human Papillomavirus DNA Testing for Cervical Cancer Screening in Rural China.

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women

High-risk HPV Nucleic Acid Detection Kit–the Care HPV Test –a New Detection Method for Screening

A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study.

Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening: the Shenzhen Cervical Cancer Screening Trial I.

Risk stratification for cervical precancer and cancer by DH3‐HPV partial genotyping and cytology in women attending cervical screening: a retrospective cohort study

The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens.

Diagnostic accuracy of extended HPV DNA genotyping and its application for risk-based cervical cancer screening strategy

The Clinical Performance of APTIMA Human Papillomavirus and Hybrid Capture 2 Assays in the Triage of Lesser Abnormal Cervical Cytologies.

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

Clinically validated HPV assays offer comparable long‐term safety in primary cervical cancer screening: A 9‐year follow‐up of a population‐based screening cohort

[Evaluation of Cobas 4800 High-Risk HPV Test As a Tool in Cervical Cancer Screening and Cytology Triage].

Polymerase Chain Reaction Human Papillomavirus (HPV) Detection and HPV Genotyping in Invasive Cervical Cancers with Prior Negative HC2 Test Results

Comparison of high-risk HPV detection by the AmpFire® HPV Screening 16/18/HR technique (Atila Biosystems) and the hybrid capture 2 test (Qiagen)

High-risk human papilloma virus DNA detection Kit(cervista HPV HR)should be highly validated clinically in cervical cancer screening programs

Comparison of Hybribio-H13 and Hybrid Capture® 2 human papillomavirus tests for detection of CIN2+ and CIN3

The Evaluation Study of Validity and Reliability of Care HPV~(TM) As a Screening Test for Cervical Cancer and Precancerous Lesions

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data